NCT00267527

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (planned)
• Sponsor: ConjuChem · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC 1295 or placebo. The objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity.

Conditions

• Obesity
• HIV Infections

Interventions

Type	Name	Description
DRUG	CJC 1295

Timeline

• Start date: 2005-12-01
• Completion: 2006-09-01
• First posted: 2005-12-21
• Last updated: 2006-10-16